RESEARCH TRIANGLE PARK, N.C., March 12, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,910,000 shares of its common stock at a public offering price of $29.50, including 510,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. G1 Therapeutics received approximately $108.4 million in proceeds from the offering, net of underwriting discounts and commissions, but before estimated offering expenses.

J.P. Morgan Securities LLC and Cowen and Company, LLC served as joint book-running managers for the offering. Needham & Company, LLC and Wedbush Securities Inc. acted as lead managers for the offering. BTIG, LLC acted as co-manager for the offering.

About G1 Therapeutics

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1’s two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of targets for anti-cancer therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as the backbone of multiple combination regimens. In addition, G1 is advancing G1T48, a potential first-/best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 is based in Research Triangle Park, NC.